- Reuters•3 hours ago
Privately held drugmaker Kaleo on Thursday said it would offer its Auvi-Q emergency allergy auto-injector at no cost to many consumers, but set a list price for the EpiPen rival that will be used as the benchmark cost to insurance companies at a whopping $4,500. EpiPen maker Mylan NV came under intense criticism last year when it raised the price for a pair of its life-saving auto-injectors to $600, putting it out of reach for many consumers. It has since said it will sell its own generic EpiPen for about half that price.
- Reuters•4 hours ago
Mylan NV has yet to reach a settlement with the U.S. Department of Justice over the classification in the Medicaid program of its life-saving EpiPen allergy treatment, according to a letter from a regulatory agency disclosed on Thursday. Mylan said in October that it would pay $465 million to resolve allegations it underpaid U.S. government healthcare programs.
- CNBC•5 hours ago
Have allergies? This EpiPen rival has a list price of $4,500, but most patients won't pay a cent.
MYL : Summary for Mylan N.V. - Yahoo Finance
Mylan N.V. (MYL)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||36.70 x 200|
|Ask||37.49 x 100|
|Day's Range||36.71 - 37.30|
|52 Week Range||33.60 - 54.23|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||74.05|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|